Paris – 28.05.2026: In an important development for the treatment of obesity in France, Minister of Health Stéphanie Rist announced today that the drugs Wegovy and Mounjaro will now be reimbursed. This decision marks an important step in the fight against obesity, which affects more than eight million people in France.
Wegovy, a drug from the Danish pharmaceutical company Novo Nordisk, had not been reimbursed in France since its introduction in October 2024 and cost patients between 274 and 365 euros per month. With the new reimbursement policy, the price for the first three doses is set at 146.91 euros per month, which represents a considerable saving for patients.
The decision to reimburse Wegovy and Mounjaro was made after intensive negotiations between the French Ministry of Health and the manufacturers. These talks focused on setting a fair price and determining the reimbursement percentage by the statutory health insurance. Although the exact details of the agreement have not yet been published, the reimbursement is expected to take effect in the second half of 2026.
The reimbursement of these drugs is expected to have significant effects on the treatment of obesity in France. Experts estimate that the annual cost of reimbursement will be around 100 million euros. This investment is considered necessary to address the rising health costs associated with obesity and to improve the quality of life of the affected patients.
Novo Nordisk has welcomed the decision of the French government and emphasized that the reimbursement of Wegovy represents an important advance in the fight against obesity. The company has also announced that it will lower the price of Wegovy in France to 146.91 euros per month for the first three doses, to further increase the accessibility of the drug.
The introduction of the reimbursement of Wegovy and Mounjaro is seen by health experts as a step in the right direction to improve the treatment of obesity in France. However, it is emphasized that a comprehensive strategy is necessary, which includes not only drug therapies but also preventive measures and an improvement in the population’s eating habits.
The French government intends to provide the public with detailed information about the reimbursement and the conditions for prescribing Wegovy and Mounjaro in the coming weeks. Patients interested in treatment with these drugs are advised to consult their general practitioner or specialist for more information and to discuss the therapy option suitable for them.
The decision to reimburse Wegovy and Mounjaro in France is considered an important step in the fight against obesity and could serve as a model for other European countries facing similar challenges. It remains to be seen how this decision will affect the prevalence of obesity and the related health costs in France.